Under a tenth of individuals who could benefit from weight-loss injections including Wegovy have access to them, states the WHO as it publishes its initial guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for broader and more equitable access to GLP-1 medication.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidelines acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key hurdles to universal access to the injections that can aid individuals in losing substantial weight, says the organization.
GLP-1 Therapy Shortage
Despite the present best projected case, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, according to the WHO.
The advice encourages nations and manufacturers to increase access, via strategies like licensing agreements.
Exclusive production rights on a key compound – the core ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Operate
These medications replicate a natural hormone to slow digestion, suppress the appetite and increase feelings of fullness so people eat less.
Patients typically see weight reduction after several weeks of starting on the once-weekly jabs.
Studies indicates users may put most of the weight back on a year later of discontinuing the drug, because their normal hunger resume.
To be carrying excess weight elevates your risk for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Obesity impacts people in every country and was responsible for millions of deaths worldwide in 2024, per the WHO.
